Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib for Brain Metastases in HER2+ Breast Cancer
NCT00263588Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2005
- Primary completion
- Sep 2007
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 2, open-label, single-arm trial of lapatinib in breast cancer, sponsored by Novartis. Primary endpoints: The Number of Participants With Central Nervous System (CNS) Best Overall Response at 2 years and The Percentage of Participants With Central Nervous System (CNS) Objective Response Rate at 2 years. Started Dec 2005; status: completed.
02
Drugs
lapatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00263588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00263588.